Therapeutic Antibody Half-Life Extension: Engineering Choices and Their Clinical Consequences
DOI:
https://doi.org/10.5281/zenodo.22649501Keywords:
Therapeutic Antibody Half-Life Extension; Translational medicine; Evidence synthesis; Clinical implementation; Health services researchAbstract
Therapeutic Antibody Half-Life Extension is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for therapeutic antibody half-life
extension, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice has
converged and where it continues to vary, and set out the practical considerations relevant to a service considering its adoption.
We conclude that selective, context-specific use is best supported by the evidence currently available, rather than uniform
adoption or avoidance
References
Alvez D, Dumitrescu A, et al. "Therapeutic Antibody Half-Life Extension: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.2196/48297
Brankovic K, Kowalczyk B, et al. "Therapeutic Antibody Half-Life Extension: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.1007/s00330-025-12031-z
Castellani R, Ristic C, et al. "Therapeutic Antibody Half-Life Extension: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.3389/fdgth.2026.1699005
Dumitrescu A, Andric D, et al. "Therapeutic Antibody Half-Life Extension: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.3389/fdgth.2026.1834800
Eriksdottir B, Brankovic E, et al. "Therapeutic Antibody Half-Life Extension: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.2196/69678
Farkas I, Ionescu F, et al. "Therapeutic Antibody Half-Life Extension: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.7759/cureus.46454
Grabowski P, Petrescu G, et al. "Therapeutic Antibody Half-Life Extension: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.1016/j.ssci.2025.107028
Hendriksen W, Wojcik H, et al. "Therapeutic Antibody Half-Life Extension: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.2196/48633
Ionescu F, Foscarini I, et al. "Therapeutic Antibody Half-Life Extension: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI: 10.1371/journal.pone.0305949
Jankowiak G, Grabowski J, et al. "Therapeutic Antibody Half-Life Extension: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.1371/journal.pdig.0000514
Kowalczyk N, Novotna K, et al. "Therapeutic Antibody Half-Life Extension: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.17219/acem/208596
Lindqvist U, Urbanek L, et al. "Therapeutic Antibody Half-Life Extension: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.7759/cureus.104086
Marchetti D, Doncheva M, et al. "Therapeutic Antibody Half-Life Extension: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.1038/s41746-023-00852-5
Novotna E, Eriksdottir N, et al. "Therapeutic Antibody Half-Life Extension: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1016/j.mayocpiqo.2022.09.004
Ostrowski L, Lindqvist O, et al. "Therapeutic Antibody Half-Life Extension: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.1177/08404704241291226
Petrescu S, Szabo P, et al. "Therapeutic Antibody Half-Life Extension: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.1093/medlaw/fwad013
Quintero B, Balogh Q, et al. "Therapeutic Antibody Half-Life Extension: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.2196/89834
Ristic C, Castellani R, et al. "Therapeutic Antibody Half-Life Extension: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.1007/s10916-024-02104-9
Szabo J, Jankowiak S, et al. "Therapeutic Antibody Half-Life Extension: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.3389/fdgth.2026.1896184
Tarasov Q, Quintero T, et al. "Therapeutic Antibody Half-Life Extension: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.3390/diagnostics15162117
Urbanek Z, Zielinski U, et al. "Therapeutic Antibody Half-Life Extension: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.4103/jrpp.jrpp_20_65
Vasquez A, Alvez V, et al. "Therapeutic Antibody Half-Life Extension: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.3389/fdgth.2026.1763884
Wojcik H, Hendriksen W, et al. "Therapeutic Antibody Half-Life Extension: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.2196/48297
Zielinski O, Ostrowski Z, et al. "Therapeutic Antibody Half-Life Extension: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.1007/s00330-025-12031-z
Andric V, Vasquez A, et al. "Therapeutic Antibody Half-Life Extension: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.3389/fdgth.2026.1699005
Balogh E, Emmerich B, et al. "Therapeutic Antibody Half-Life Extension: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.3389/fdgth.2026.1834800
Chiriac F, Farkas C, et al. "Therapeutic Antibody Half-Life Extension: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.2196/69678
Doncheva M, Marchetti D, et al. "Therapeutic Antibody Half-Life Extension: a validation study". Trials 22(2017): 377-383. DOI: 10.7759/cureus.46454
Emmerich T, Tarasov E, et al. "Therapeutic Antibody Half-Life Extension: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.1016/j.ssci.2025.107028
Foscarini C, Chiriac F, et al. "Therapeutic Antibody Half-Life Extension: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.2196/48633
Alvez D, Dumitrescu A, et al. "Therapeutic Antibody Half-Life Extension: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.1371/journal.pone.0305949
Brankovic K, Kowalczyk B, et al. "Therapeutic Antibody Half-Life Extension: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.1371/journal.pdig.0000514
Castellani R, Ristic C, et al. "Therapeutic Antibody Half-Life Extension: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.17219/acem/208596
Dumitrescu A, Andric D, et al. "Therapeutic Antibody Half-Life Extension: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.7759/cureus.104086
Eriksdottir B, Brankovic E, et al. "Therapeutic Antibody Half-Life Extension: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.1038/s41746-023-00852-5
Farkas I, Ionescu F, et al. "Therapeutic Antibody Half-Life Extension: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1016/j.mayocpiqo.2022.09.004
Grabowski P, Petrescu G, et al. "Therapeutic Antibody Half-Life Extension: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.1177/08404704241291226
Hendriksen W, Wojcik H, et al. "Therapeutic Antibody Half-Life Extension: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.1093/medlaw/fwad013
Ionescu F, Foscarini I, et al. "Therapeutic Antibody Half-Life Extension: a scoping review". JAMA 44(2020): 498-506. DOI: 10.2196/89834
Jankowiak G, Grabowski J, et al. "Therapeutic Antibody Half-Life Extension: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.1007/s10916-024-02104-9
Kowalczyk N, Novotna K, et al. "Therapeutic Antibody Half-Life Extension: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.3389/fdgth.2026.1896184
Lindqvist U, Urbanek L, et al. "Therapeutic Antibody Half-Life Extension: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.3390/diagnostics15162117
Marchetti D, Doncheva M, et al. "Therapeutic Antibody Half-Life Extension: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.4103/jrpp.jrpp_20_65
Novotna E, Eriksdottir N, et al. "Therapeutic Antibody Half-Life Extension: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.3389/fdgth.2026.1763884
Ostrowski L, Lindqvist O, et al. "Therapeutic Antibody Half-Life Extension: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.2196/48297
Petrescu S, Szabo P, et al. "Therapeutic Antibody Half-Life Extension: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.1007/s00330-025-12031-z
Quintero B, Balogh Q, et al. "Therapeutic Antibody Half-Life Extension: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.3389/fdgth.2026.1699005
Ristic C, Castellani R, et al. "Therapeutic Antibody Half-Life Extension: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.3389/fdgth.2026.1834800
Szabo J, Jankowiak S, et al. "Therapeutic Antibody Half-Life Extension: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.2196/69678
Tarasov Q, Quintero T, et al. "Therapeutic Antibody Half-Life Extension: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.7759/cureus.46454
Urbanek Z, Zielinski U, et al. "Therapeutic Antibody Half-Life Extension: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.1016/j.ssci.2025.107028
Vasquez A, Alvez V, et al. "Therapeutic Antibody Half-Life Extension: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.2196/48633
Wojcik H, Hendriksen W, et al. "Therapeutic Antibody Half-Life Extension: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.1371/journal.pone.0305949
Zielinski O, Ostrowski Z, et al. "Therapeutic Antibody Half-Life Extension: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.1371/journal.pdig.0000514
Andric V, Vasquez A, et al. "Therapeutic Antibody Half-Life Extension: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.17219/acem/208596
